公开(公告)号：US20220098278A1

公开(公告)日：2022-03-31

申请号：US17490505

申请日：2021-09-30

申请人： Oncolmmune, Inc. ,  Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Ning Li

IPC分类号： C07K14/705 ,  A61P25/00

摘要： The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders

公开(公告)号：US20210214458A1

公开(公告)日：2021-07-15

申请号：US17055248

申请日：2019-05-13

申请人： ONCOIMMUNE, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Rhonda Flores ,  Hung-Yen Chou ,  Zhihong Xue ,  Peiying Ye ,  Martin Devenport

IPC分类号： C07K16/28 ,  A61P35/00

摘要： Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.

公开(公告)号：US11261233B2

公开(公告)日：2022-03-01

申请号：US16333888

申请日：2017-09-19

申请人： ONCOC4, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Wei Wu ,  Xuexiang Du ,  Mingyue Liu ,  Fei Tang

IPC分类号： C07K14/705 ,  C07K16/46 ,  A61K38/00 ,  A61P37/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  C07K14/00 ,  A61K39/00

摘要： This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

公开(公告)号：US11116726B2

公开(公告)日：2021-09-14

申请号：US15774217

申请日：2016-11-09

申请人： CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Yin Wang ,  Yan Liu ,  Christopher Bailey ,  Pan Zheng

IPC分类号： A61K9/127 ,  A61K38/16 ,  A61K47/69 ,  A61K35/74 ,  A61P37/02 ,  A61P35/02

摘要： A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

公开(公告)号：US20200171068A1

公开(公告)日：2020-06-04

申请号：US16614505

申请日：2018-05-18

申请人： Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Toshihiko Tanno

IPC分类号： A61K31/713 ,  C12N15/115 ,  C12N15/113 ,  A61K45/06 ,  A61P7/00 ,  A61P35/00

摘要： The disclosure relates to compositions comprising a nucleic acid sequence having two domains: a cell targeting domain and a microRNA domain, wherein the cell targeting domain comprises an aptamer sequence that targets cancer cells and the microRNA domain comprises a microRNA sequence that binds to an endogenous mRNA sequence within a cancer cell and disrupts normal function of the cell.

公开(公告)号：US20210047410A1

公开(公告)日：2021-02-18

申请号：US16967065

申请日：2019-01-29

申请人： oncolmmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC分类号： C07K16/28 ,  A61P35/00 ,  C12N5/071 ,  C12N5/0783 ,  G01N33/58

摘要： The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US11547741B2

公开(公告)日：2023-01-10

申请号：US16614660

申请日：2018-05-21

申请人： ONCOIMMUNE, INC. ,  CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Mingyue Liu

IPC分类号： A61K38/17 ,  A61P37/06 ,  C07K14/705

摘要： The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.

公开(公告)号：US20220000974A1

公开(公告)日：2022-01-06

申请号：US17428784

申请日：2020-02-05

申请人： Oncolmmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Xu Wang ,  Martin Devenport

IPC分类号： A61K38/17 ,  C07K14/705 ,  A61P3/06 ,  A61P3/10

摘要： Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.

公开(公告)号：US10898522B2

公开(公告)日：2021-01-26

申请号：US15753901

申请日：2016-08-18

申请人： Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Yin Wang

IPC分类号： A61K35/28 ,  A61K38/08 ,  A61K38/17 ,  A61K38/16 ,  A61P37/06 ,  A61P35/02 ,  A61K31/7105 ,  A61K48/00

摘要： A method of preventing the development of GvHD or reducing the severity of GvHD in a mammalian subject receiving an allogeneic hematopoietic stem cell (HSC) transplant includes administering to the subject a pharmaceutical composition comprising an active agent that inhibits the biological activity or expression of hypoxia-inducible factor-1a (HIF-1a) or hypoxia-inducible factor-2a (HIF-2a), wherein the active agent is administered in an amount effective for preventing or reducing the severity GvHD in the subject.